Design Therapeutics, Inc. (DSGN) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-97.5%

$0.26

vs $10.15 price

Levered DCF

$0.27

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

26.54

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-7.69×	-7.01×	-2.23×	-9×	-27.81×	-138.3×	-551×
P/B	2.53×	1.44×	0.53×	1.75×	2.57×	-99.7×	-309.75×
P/S	0×	0×	0×	0×	0×	0×	1,352,653.6×
EV / EBITDA	-7.55×	-6.71×	-1.96×	-8.72×	-19.45×	-136.04×	-8,120.37×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-98.3%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-228777.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-245443.6%
Current ratio	17.14×	29.31×	29.58×	31.1×	72.96×	15.55×	0.02×
Debt / equity	0.01×	0.01×	0.01×	0.01×	0.01×	0×	-0.19×
Interest coverage	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-32.8%	-20.5%	-24.1%	-19.3%	-9.3%	73.2%	56.2%
Return on invested capital	-37.1%	-25.5%	-27.9%	-20.4%	-9.3%	-25.0%	64.8%
Return on assets	-30.9%	-19.7%	-23.1%	-18.6%	-9.1%	-22.7%	-2274.4%
Free cash flow yield	-10.1%	-12.4%	-39.6%	-9.1%	-3.1%	-0.8%	-0.0%
Earnings yield	-13.0%	-14.2%	-45.1%	-11.1%	-3.6%	-0.7%	-0.2%
Enterprise value	$522.4M	$328.9M	$130.2M	$548.8M	$688.6M	$1.1B	$1.1B
Net debt / EBITDA	0.22×	0.41×	0.27×	0.36×	8.33×	0.29×	-4.45×
Cash conversion cycle (days)	0	0	-1,319	-2,369	0	-102,127	-547,059